2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

ADC human IgG1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

3

Fluorescent Dye

18

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164154
    ADC Control Human IgG1-vcMMAF

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
    ADC Control Human IgG1-vcMMAF
  • HY-164153
    ADC Control Human IgG1-vcMMAE (solution)

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
    ADC Control Human IgG1-vcMMAE (solution)
  • HY-164152
    ADC Control Human IgG1-Deruxtecan (DAR 4)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 4)
  • HY-164152A
    ADC Control Human IgG1-Deruxtecan (DAR 8)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 8)
  • HY-164954
    ADC Control Human IgG1-McMMAF

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).
    ADC Control Human IgG1-McMMAF
  • HY-164669
    ADC Control Human IgG1-DM4

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
    ADC Control Human IgG1-DM4
  • HY-164668
    ADC Control Human IgG1-SN-38

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).
    ADC Control Human IgG1-SN-38
  • HY-159774
    ADC Control human IgG1-DM1

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .
    ADC Control human IgG1-DM1
  • HY-145626
    Ozuriftamab
    1 Publications Verification

    BA302

    		 ADC Antibody ROR Cancer
    Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ozuriftamab
  • HY-P991204
    Anti-PSMA Antibody

    ARX517 antibody

    		 PSMA Cancer
    Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-PSMA Antibody
  • HY-P99233
    Camidanlumab

    HuMax-TAC

    		 ADC Antibody Transmembrane Glycoprotein Interleukin Related Cancer
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Camidanlumab
  • HY-P991197
    Anti-GPRC5D Antibody

    LM-305 antibody; AZD-0305 antibody

    		 CD3 Cancer
    Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-GPRC5D Antibody
  • HY-P991041
    Turmetabart

    Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody

    		 ADC Antibody Cancer
    Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Turmetabart
  • HY-P99970
    Lifastuzumab

    		ADC Antibody Sodium Phosphate Cotransporter Cancer
    Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lifastuzumab
  • HY-P99271
    Tisotumab

    Anti-human F3 Recombinant Antibody

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99271A
    Tisotumab (powder)

    Anti-human F3 Recombinant Antibody (powder)

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
    Tisotumab (powder)
  • HY-P99234
    Pivekimab

    		Interleukin Related ADC Antibody Cancer
    Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
    Pivekimab
  • HY-P99656
    Iladatuzumab

    MCDS0593A

    		 ADC Antibody Cancer
    Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
    Iladatuzumab
  • HY-P99813
    Patritumab deruxtecan

    HER3-DXd; U3-1402

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
    Patritumab deruxtecan
  • HY-P99230
    Pinatuzumab

    		Integrin CD22 Cancer
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Pinatuzumab
  • HY-P99229
    Upifitamab
    2 Publications Verification

    		 ADC Antibody Cancer
    Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Upifitamab
  • HY-164957
    SGN-B6A

    		Antibody-Drug Conjugates (ADCs) Integrin Cancer
    SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
    SGN-B6A
  • HY-141599
    Camidanlumab tesirine

    ADCT 301

    		 Antibody-Drug Conjugates (ADCs) Interleukin Related Cancer
    Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
    Camidanlumab tesirine
  • HY-P991640
    Anti-TDGF1 antibody (huB3F6)

    BIIB015 antibody

    		 ADC Antibody Cancer
    Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of ADCs .
    Anti-TDGF1 antibody (huB3F6)
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
    MC-GGFG-AM-(10Me-11F-Camptothecin)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: